The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)